Patriot Financial Group Insurance Agency LLC Sells 84 Shares of Cencora, Inc. (NYSE:COR)

Patriot Financial Group Insurance Agency LLC cut its position in shares of Cencora, Inc. (NYSE:COR) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,983 shares of the company’s stock after selling 84 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Cencora were worth $896,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of COR. New Millennium Group LLC bought a new stake in shares of Cencora during the second quarter valued at approximately $26,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the first quarter valued at approximately $29,000. TFO Wealth Partners LLC bought a new stake in shares of Cencora during the first quarter valued at approximately $30,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora during the second quarter valued at approximately $30,000. Finally, Concord Wealth Partners bought a new stake in shares of Cencora during the third quarter valued at approximately $30,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Cencora stock opened at $233.61 on Tuesday. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The firm has a market cap of $46.59 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.40 and a beta of 0.44. The business’s fifty day moving average is $232.15 and its two-hundred day moving average is $230.76. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the previous year, the firm earned $2.92 earnings per share. The business’s revenue was up 10.8% on a year-over-year basis. Equities research analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Activity

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,461,153 shares of company stock valued at $1,073,075,720 over the last 90 days. 15.80% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on COR shares. Bank of America reiterated a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Wells Fargo & Company upped their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Robert W. Baird lowered their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $259.44.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.